Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer
Prof. Karim Fizazi
Efficacy of single-agent immunotherapy for patients with metastatic castration-resistant prostate cancer has been suboptimal, leading to the recent investigation of combination therapies. In two cohorts of the phase 2 CheckMate 9KD trial, activity was seen with the combination of nivolumab (anti-PD-1) and rucaparib (PARP inhibitor) for HRD-positive postchemotherapy or chemotherapy-naïve mCRPC, especially in patients harboring BRCA1/2 mutations. The combination had an acceptable safety profile.
